BOSTON (March 31, 2016)--Researchers at Boston Children's Hospital show how brain connections, or synapses, are lost early in Alzheimer's disease and demonstrate that the process starts -- and could potentially be halted -- before telltale plaques accumulate in the brain. Their work, published online by Science on March 31, suggests new therapeutic targets to preserve cognitive function early in Alzheimer's disease.
Led by Beth Stevens, PhD, and Soyon Hong, PhD, of Boston Children's F.M. Kirby Neurobiology Center, the researchers show in multiple mouse models of Alzheimer's that mechanisms similar to those used to "prune" excess synapses in the healthy developing brain are wrongly activated later in life. By blocking these mechanisms, they were able to reduce synapse loss in the mice.
Currently, there are five FDA-approved drugs for Alzheimer's, but these only boost cognition temporarily and do not address the root causes of cognitive impairment in Alzheimer's. Many newer drugs in the pipeline seek to eliminate amyloid plaque deposits or reduce inflammation in the brain, but the new research from Boston Children's suggests that Alzheimer's could be targeted much earlier, before these pathologic changes occur.
"Synapse loss is a strong correlate of cognitive decline," says Stevens, assistant professor in the Department of Neurology at Boston Children's, senior investigator on the study and a recent recipient of the MacArthur "genius" grant. "We're trying to go back to the very beginning and see how synapse loss starts."
The young brain informing the old
Stevens, Hong and colleagues looked at Alzheimer's -- a disease of aging -- through an unusual lens: normal brain development in infancy and childhood. Through years of research, the Stevens lab has shown that normal developing brains have a process to "prune" synapses that aren't needed as they build their circuitry. (See accompanying backgrounder.)
"Understanding a normal developmental process deeply has provided us with novel insight into how to protect synapses in Alzheimer's and potentially a host of other diseases," says Stevens, noting that synapse loss also occurs in frontotemporal dementia, Huntington's disease, schizophrenia, glaucoma and other conditions.
In the Alzheimer's mouse models, the team showed that synapse loss requires the activation of a protein called C1q, which "tags" synapses for elimination. Immune cells in the brain called microglia then "eat" the synapses -- similar to what occurs during normal brain development. In the mice, C1q became more abundant around vulnerable synapses before amyloid plaque deposits could be observed.
When Stevens and colleagues blocked C1q, a downstream protein called C3, or the C3 receptor on microglia, synapse loss did not occur.
"Microglia and complement are already known to be involved in Alzheimer's disease, but they have been largely regarded as a secondary event related to plaque-related neuroinflammation, a prominent feature in progressed stages of Alzheimer's," notes Hong, the Science paper's first author. "Our study challenges this view and provides evidence that complement and microglia are involved much earlier in the disease process, when synapses are already vulnerable, and could potentially be targeted to preserve synaptic health."
A human form of the antibody Stevens and Hong used to block C1q, known as ANX-005, is in early therapeutic development with Annexon Biosciences (San Francisco) and is being advanced into the clinic. The researchers believe it has potential to be used someday to protect against synapse loss in a variety of neurodegenerative diseases.
"One of the things this study highlights is the need to look for biomarkers for synapse loss and dysfunction," says Hong. "As in cancer, if you treat people at a later stage of Alzheimer's, it may already be too late."
Complement, microglia and beta-amyloid
Together with co-author Dennis Selkoe, MD, at Brigham and Women's Hospital, the researchers also found that that beta-amyloid protein, C1q and microglia work together to cause synapse loss in the early stages of Alzheimer's. The oligomeric form of beta-amyloid (multiple units of beta-amyloid strung together) is already known to be toxic to synapses even before it forms plaque deposits, but the study showed that C1q is necessary for this effect. The converse was also true: microglia engulfed synapses only when oligomeric beta-amyloid was present.
Annexon co-founders Ben Barres, MD, PhD, and Arnon Rosenthal, PhD, are coauthors on the paper. Barres, Rosenthal and Stevens are minor shareholders of Annexon LLC and Stevens is a member of the Scientific Advisory Board. The study was funded by Edward R. and Anne G. Lefler Fellowship, Coins for Alzheimer's Research Trust, Fidelity Biosciences Research Initiative (F-Prime), JPB Foundation and the National Institutes of Health (AG000222), NINDS-NIH R01NS083845 and the NIH National Institute on Aging (1RF1AG051496A).
About Boston Children's Hospital
Boston Children's Hospital is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including seven members of the National Academy of Sciences, 11 members of the Institute of Medicine and 10 members of the Howard Hughes Medical Institute comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's today is a 404-bed comprehensive center for pediatric and adolescent health care. Boston Children's is also the primary pediatric teaching affiliate of Harvard Medical School. For more, visit our Vector and Thriving blogs and follow us on our social media channels: @BostonChildrens, @BCH_Innovation, Facebook and YouTube.